INTRODUCTION TO LLS THERAPY ACCELERATION PROGRAM

December 2019
BLOOD CANCERS

Every 3 minutes someone in the US is diagnosed with a blood cancer.

More than one third of blood cancer patients do not survive five years after diagnosis.

Despite improved outcomes, we need to do more!
OUR MISSION

Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families

More than $1.3 billion invested in research

Unparalleled patient support and education services

Advocacy to accelerate cures and access
LLS Research focuses on discovering and developing therapies to positively impact care for blood cancer patients.
Research by Funding Mechanism - FY18

- TRP 32%
- CDP 20%
- SCOR 18%
- TAP 12%
- Canada 7%
- MCL 4%
- SLP 2%
- Other 5%

$52.6 Million
Therapy Acceleration Program (TAP)

- Strategic initiative established in 2007
- Accelerate high-risk innovative blood cancer therapeutics
- Meeting LLS Mission is first priority
- Generating ROI to further fund LLS Mission is secondary

LLS TAP

Biotechnology Accelerator
Co-funding up to 50%

Academic Concierge
Funding up to 100%
Therapy Acceleration Program (TAP) Supports Emerging New Therapies

- Venture Philanthropy since 2007
- $120M+ investment
- 60+ projects
- 16 in current portfolio

- 3 FDA Approvals
  - Vyxeos (AML)
  - Yescarta (DLBCL, tFL, PMBCL)
  - Elzonris (BPDCN)

www.lls.org/therapy-acceleration-program
# Development Stages of TAP Portfolio

<table>
<thead>
<tr>
<th>Development Phase</th>
<th>Current</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase II Reg / Phase III</td>
<td>2</td>
<td>7</td>
</tr>
<tr>
<td>Phase II (Non Registration)</td>
<td>7</td>
<td>12</td>
</tr>
<tr>
<td>Phase I</td>
<td>5</td>
<td>25</td>
</tr>
<tr>
<td>Preclinical</td>
<td>1</td>
<td>16</td>
</tr>
<tr>
<td>Clinical Trial Networks/ Patient Care</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>16</strong></td>
<td><strong>64</strong></td>
</tr>
</tbody>
</table>

**Current Focus:** Clinical Proof of Concept
<table>
<thead>
<tr>
<th>THERAPY</th>
<th>TARGET/MODALITY</th>
<th>INDICATION(S)</th>
<th>PHASE I</th>
<th>PHASE II</th>
<th>PHASE II REG/PHASE III</th>
</tr>
</thead>
<tbody>
<tr>
<td>Magrolimab + azacitidine</td>
<td>Anti-CD47 Antibody</td>
<td>MDS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cobomarsen</td>
<td>miR-155 Small Molecule</td>
<td>Cutaneous T-cell Lymphoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Magrolimab + rituximab</td>
<td>Anti-CD47 Antibody</td>
<td>Lymphoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COPIKTRA (duvelisib)</td>
<td>PI3Kδ/γ Small Molecule</td>
<td>Peripheral T-cell Lymphoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>X4P-001 + ibrutinib</td>
<td>CXCR4 Small Molecule</td>
<td>Waldenstrom Macroglobulinemia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STRO-001</td>
<td>Anti-CD74 Antibody Drug Conjugate</td>
<td>Lymphoma Myeloma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SEL120</td>
<td>CDK8/19 Small Molecule</td>
<td>AML</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NEXI-001</td>
<td>Cell Therapy</td>
<td>Post-transplant AML</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>JNJ-40346527</td>
<td>CSF-1R Small Molecule</td>
<td>AML</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NK cells + ALT-803</td>
<td>Cell Therapy</td>
<td>Heme Malignancies</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Select Projects in Current TAP Portfolio**

*LEUKEMIA & LYMPHOMA SOCIETY*

**BEATING CANCER IS IN OUR BLOOD.**
LLS TAP Process

- Open to funding application year round
- All hematological indications
- Focuses on therapeutics development in the clinic
- Typically $2-6M dollars (co-funding for companies)
  - equity or milestone based
- Applicants fill out 1-page Inquiry Form to start the process

How to apply for TAP: www.lls.org/therapy-acceleration-program
LLS TAP Funding Is Competitive

Average annual number; typically 3-6 month to reach TAP Committee Review
LLS TAP Committee

- Subcommittee of LLS National Board
- Members consist of KOLs, IP lawyer, VC-investors in biotech, Industry veterans
- TAP Research performs S&E and recommends TAP projects to the Committee
- Company presents to the TAP Committee
- The Committee may approve, conditionally approve or reject company funding request
- Committee approval provides Research BD to proceed to Term Sheet and then formal Agreement
Key Criteria

- High Unmet Medical Need
- Innovative Science
- First-in-Class
- High potential to impact clinical practice
- Clinical PoC Study or Registration-Directed Study
- Strong IP Position
- Competent Management Team
- Solid Corporate Finance
Why Companies Come to TAP in addition to $$

- Deep knowledge of blood cancer landscape
- Expertise in hem/onc clinical development within LLS and via KOLs
- Connections to patients
- Advocacy efforts for patients
- Biotech companies leverage LLS approval to raise additional funds
- Track record of success
TAP is Bridging the Gap for Biotech
We have one goal: A world without blood cancers

THANK YOU
FY18 Research Spend by Disease

- **Research Budget: $52.6 Million**

- **Aggressive NHL**: $12.0 M (23%)
- **AML**: $13.2 M (25%)
- **Myeloma**: $7.2 M (14%)
- **MDS/MPNs**: $5.1 M (10%)
- **Indolent NHL**: $3.1 M (6%)
- **General Lymphoma**: $3.2 M (6%)
- **ALL**: $2.5 M (5%)
- **CLL/SLL**: $1.6 M (3%)
- **CML**: $0.6 M (1%)
- **Hodgkin Lymphoma**: $0.9 M (2%)
Unmet Medical Need

- An indication with no standard of care
- An indication where standard of care yield unsatisfactory outcomes
- A substantial population of patients relapse from or are refractory to currently available treatment options
- Current standard of care include unfavorable toxicity - Chemo-free or less toxic treatments if efficacy is not compromised
- A more convenient regimen to benefit a large portion of the patients with the disease - Oral vs. IP or IV for indolent disease management